Patent application number | Description | Published |
20080206210 | Drugs for the Prevention or Treatment of Immunodeficiencies, Autoimmune Diseases or for the Induction of Immune Tolerance - The invention relates to the use of viral vectors able to stably integrate into the genome of thymic stromal cells, or of intrathymic lymphocytes or lymphocytes precursors, for the manufacture of a medicine intended for intrathymic administration in the frame of the prevention or treatment of genetic immunodeficiencies, acquired immunodeficiencies, or for the induction of immune tolerance of the organism to self or non-self gene products, cells or tissues, or for the prevention or treatment of autoimmune diseases. | 08-28-2008 |
20100215629 | TREATMENT OF TUMORS USING T LYMPHOCYTE PREPARATIONS - The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment. | 08-26-2010 |
20100233144 | METHOD FOR OPTIMIZING BLOOD CELL TRANSPLANTS - The invention relates to the use of allogenic T lymphocytes for the preparation of a composition intended to be injected into a recipient patient as a conditioning for a transplantation of haematopoietic stem cells, said allogenic T lymphocytes expressing a molecule allowing their specific destruction. | 09-16-2010 |
20140004080 | USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE - RELATED OR INFLAMMATORY DISORDERS | 01-02-2014 |
20140236621 | METHOD FOR DETERMINING A PREDICTIVE FUNCTION FOR DISCRIMINATING PATIENTS ACCORDING TO THEIR DISEASE ACTIVITY STATUS - The invention relates to a method for determining a predictive function for discriminating patients according to their disease activity status, comprising steps of: a—measuring values of biological markers for each patient of a first group of patients having a first known disease activity status, and for each patient of a second group of patients having a second known disease activity status, the measured values forming a dataset b—analyzing the dataset for identifying biological markers which are differentially expressed between the first group of patients and the second group of patients, c—among the biological markers identified at step b, determining correlated markers as markers which are correlated with other markers above a predetermined significance level, d—removing from the dataset, values measured for a biological marker identified as correlated marker, e—analyzing the dataset obtained at step d for determining a predictive function that predicts a disease activity status of a patient as a combination of values of biological markers, f—evaluating an accuracy index associated with the predictive function determined at step e, g—repeating steps d to f by selectively removing from the dataset, values measured for one or several biological marker(s) identified as correlated marker(s), so as to gradually decrease the number of biological markers in the combination of value until the accuracy index reaches an expected level. | 08-21-2014 |
20140255445 | SYNTHETIC VIRUSES AND USES THEREOF - The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response. | 09-11-2014 |